Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

Maycon schreef op 2 mei 2015 11:07:

Jammer dat er altijd bij dit soort ontwikkelingen er weer bashers om de hoek komen kijken....

quote:

adje5 schreef op 2 mei 2015 09:30:

Het Galapagos verhaal MOET positief aflopen!

Galapagos heeft warrants gecreeerd voor werknemers

AMSTERDAM (Dow Jones)--Galapagos nv (GLPG.AE) heeft warrants gecreeerd en aangeboden aan werknemers en bestuurders, meldt het biotechbedrijf vrijdag.

In totaal zijn er 625.740 warrants gemaakt. Deze zijn hoofdzakelijk aan werknemers aangeboden en ook aan bestuurders.

De warrants hebben een uitoefentermijn van 8 jaar vanaf de datum van het aanbod en een uitoefenprijs van EUR28,75. Ze zijn niet overdraagbaar en krijgen geen notering.

Ieder warrant geeft het recht om in te schrijven op 1 nieuw aandeel Galapagos.

----------------------------- - See more at: beursig.nl/forum/viewtopic.php?f=4&am...

Dit zeg toch genoeg,op naar het goud.Eind dit jaar rond de 100 als ze nog genoteerd staan.

Fijn weekend ieder

quote:

SJURVM schreef op 1 mei 2015 21:48:

Yes that is part of the "risk factors" one has to put in a prospectus.

I think this has been discussed at length on this forum as to why Abbvie would do such a thing. Unless their own was as good as filgotinib.
On the balance of probabilities Abbvie is in more need to replace Humira with another blockbuster than not do the right commercial thing.

Financially a take-over is cheaper (and they would get the other programs too).

But yes if the so wished for whatever reason to could leave the grapes to dry out on the vine as it were.

quote:

grapesharvester schreef op 2 mei 2015 12:25:

[...]

You will understand that I am quite against anyone who wants grapes to dry out on the vine. Nurturing the grapes and the vines is much better and the grapes need to be harvested every year at the right time.

I expect that Onno has taken good note of the developments at Crucell with the Sanofi flu project and that he has inserted sufficient contractual stipulations in the contract with ABBVIE to avoid such from happening with 634.

Also the situation is now quite different as the production process of 634 is not that a dramatic shift (triggering write offs) as it would have been for Sanofi to move from flu production in eggs to cell culture.
Also 634 promises to wipe out biosimilar (TNF) competition currently threatening Humira.

Yes I much prefer to harvest the grapes and drinking the good wine made from them.
I can't indeed believe that Abbvie would go down that route as it would make no commercial sense whatsoever.
I know some people are concerned that Abbvie's own drug might be as good as 0634 but again on this forum it has been discussed Harrysnel? aston.martin? that it is not quite the real McCoy.

The real question is what is the cheapest option for Abbvie?

Considering the difficulties they are having in acquiring Pharmacyclics where not all shareholders have tendered their shares ( are they waiting for a higher offer?) it might not go for a take-over after all. But then those payments and royalities....

We shall wait and see.

Next step is Nasdaq. Wider institutional ownership. Money raised will serve to replace the cash burn this year and next.

Who knows, if still independent, a new issue will be raised in 2016 but in Europe this time with the likes of KBC & UBS etc to keep them sweet? THis to pay for the development of the drugs in the pipeline.

One way or another the price will move upwards with time.